You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

List of Excipients in Branded Drug HEARTBURN RELIEF 150


✉ Email this page to a colleague

« Back to Dashboard


Excipient Strategy and Commercial Opportunities for Heartburn Relief 150

Last updated: March 21, 2026

What are the key excipient considerations for Heartburn Relief 150?

Excipients play a crucial role in formulation stability, bioavailability, patient compliance, and manufacturing efficiency. An optimal excipient strategy for Heartburn Relief 150, an over-the-counter (OTC) antacid, requires aligning with regulatory standards, ensuring active drug stability, and enhancing product appeal.

Common excipients in antacid formulations:

  • Binders: Microcrystalline cellulose, povidone.
  • Disintegrants: Croscarmellose sodium, sodium starch glycolate.
  • Lubricants: Magnesium stearate, stearic acid.
  • Fillers/diluents: Lactose, anhydrous dibasic calcium phosphate.
  • Flavoring agents: Natural and artificial flavors.
  • Sweeteners: Aspartame, sucralose, sorbitol.
  • Colors: FD&C dyes relevant to packaging regulation.

Selection criteria:

  • Compatibility with the active ingredient, aluminum hydroxide or magnesium hydroxide.
  • Non-reactivity under manufacturing and storage conditions.
  • Safety profile compliant with OTC monographs.
  • Ease of manufacturing and cost-effectiveness.

Formulation challenges:

  • Maintaining pH stability to preserve drug efficacy.
  • Managing excipient interactions that might lead to discoloration or degradation.
  • Ensuring rapid disintegration and absorption to provide quick relief.

What regulatory considerations impact excipient strategy?

Regulatory pathways influence excipient selection significantly.

  • FDA OTC monograph: Provides approved excipient lists for antacids, minimizing regulatory risk.
  • EU regulations: Require detailed excipient safety data and declaration.
  • International standards: USP, EP, JP, and other pharmacopoeias specify permissible excipients with specifications.

Any new excipient introduced must undergo safety assessment and permissible limits validation.

How does excipient choice affect commercial opportunities?

  • Brand differentiation: Incorporating natural flavors or unique sweeteners can appeal to health-conscious consumers.

  • Extended shelf life: Selecting excipients with superior stability profiles reduces packaging and distribution costs.

  • Formulation innovation: Moving beyond traditional tablets to chewable or effervescent forms can expand market reach. This entails specific excipient strategies (e.g., effervescent agents like citric acid, sodium bicarbonate).

  • Manufacturing scalability: Employing excipients that facilitate high-speed filling and compression enhances production efficiency.

  • Regulatory approval: Using well-established excipients limits time-to-market and reduces approval risk, protecting market share.

What are the emerging opportunities?

  • Natural excipients: Plant-based fillers and flavoring agents align with consumer trends toward cleaner labels (e.g., stevia extracts, natural flavors).

  • Novel delivery systems: Liposomal or nanocarrier approaches require specialized excipients, potentially offering faster relief or targeted delivery.

  • Personalized formulations: Customized dosage forms with excipients tailored for specific demographics (e.g., pediatric or elderly populations).

  • Sustainable excipients: Biodegradable and renewable excipients reduce environmental impact and meet regulatory expectations.

Market Trends and Potential

Parameter Data Point
Global antacid market USD 4.3 billion in 2022, CAGR 4.6% (Research and Markets[1])
OTC segment 75% of heartburn management sales in key markets
Consumer preferences Natural ingredients, minimal artificial additives
Packaging innovations Single-dose blister packs, eco-friendly containers

Formulation flexibility and alignment with consumer preferences define commercial success.

Summary of key findings

  • Excipient compatibility with active ingredients is critical for stability and efficacy.
  • Regulatory pathways favor established excipients; innovation must align with safety approvals.
  • Market opportunities include natural, sustainable, and innovative delivery forms.
  • Formulation choices influence manufacturing costs, shelf life, and consumer appeal.

Key Takeaways

  • Formulation strategies should prioritize excipients approved under relevant OTC monographs, emphasizing safety, stability, and manufacturability.
  • Innovation in delivery systems offers profitable avenues, provided excipient compatibility is maintained.
  • Consumer trends push for natural and sustainable excipients, creating new product differentiation.

FAQs

1. Can new excipients be used in OTC antacid formulations?
Yes, but they require regulatory approval, including safety data and compliance with monograph standards.

2. How do excipients influence shelf life?
Excipients impact stability; choices like antioxidants or desiccants help extend product shelf life.

3. Are natural excipients suitable for heartburn relief formulations?
They are increasingly favored by consumers and can be used if they meet safety and stability requirements.

4. What excipient innovations are trending for OTC antacids?
Effervescent agents, natural flavoring, and biodegradable fillers.

5. How does excipient selection affect manufacturing costs?
Using readily available, standard excipients reduces complexity and costs, enabling scalable production.

References

[1] Research and Markets. (2022). Global Antacid Market Report.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.